Efficacy of Lactobacillus gasseri on aspirin induced small intestinal injuries - a double-blind, placebo- controlled study

Efficacy of Lactobacillus gasseri on aspirin induced small intestinal injuries - a double-blind, placebo- controlled study - Lactobacillus prevents aspirin induced small intestinal injuries

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000015866

Enrollment

Registered

2014-12-06

Start date

2013-09-13

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

aspirin induced small intestinal injuries

Interventions

Aspirin plus LG Aspirin plus placebo

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: regular users of aspirin who have already used more than 4 weeks, and continue to use further over 6 weeks

Exclusion criteria

Exclusion criteria: 1. patients taking misoprostol 2. patients taking other NSAIDs, steroid, anti-platelet agents except aspirin, anti-coagulants, or anti-cancer drugs 3. patients with contraindication to capsule endoscopy 4. patients with active bleeding lesions 5. pregnancy 6. severely ill patients

Design outcomes

Primary

Measure	Time frame
grade, number, and improvement of small intestinal lesions evaluated by capsule endoscopy	—

Secondary

Measure	Time frame
Symptom improvement after taking LG	—

Countries

Japan

Contacts

Public ContactTakayoshi Suzuki

Tokai University School of Medicine Division of Gastroenterology & Hepatology

takayosh@is.icc.u-tokai.ac.jp0463-93-1121

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026